Cagrisema

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2ObesityOverweightType 2 Diabetes

Phase 2

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

WithdrawnNCT07357740

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2026-08-27End: 2027-10-13Updated: 2026-07-09

Phase 3

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

WithdrawnNCT07357766

Novo Nordisk A/SObesity, Overweight

Start: 2026-06-22End: 2028-01-17Updated: 2026-07-09

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

RecruitingNCT07564414

Novo Nordisk A/SObesity, Type 2 Diabetes

Start: 2026-05-21End: 2028-04-19Target: 2500Updated: 2026-08-31

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Not yet recruitingNCT07817251

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2026-09-16End: 2027-07-21Target: 210Updated: 2026-09-14